Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 20 de 237 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Taylor P. COVID-19 round-up: medicines on trial. PMLiVE 2020:9 de junio. [Ref.ID 103659]
2. Cita con resumen
Lee M, Sun J, Han M, Cho Y, Lee J-Y, Nam CM, Kang ES. Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors. Diabetes Care 2019;422:noviembre. [Ref.ID 103217]
3. Cita con resumen
Anónimo. FDA approves first oral GLP-1 treatment for type 2 diabetes. FDA 2019:1. [Ref.ID 103193]
4.Enlace a cita original Cita con resumen
Ueda P, Svanström H, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018;363:14 de noviembre. [Ref.ID 102869]
6. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
7. Cita con resumen
Lin H-F, Liao KF, Chang C-M, Lin CL, Lai S-W. Association of use of selective serotonin reuptake inhibitors with risk of acute pancreatitis: a case-control study in Taiwan. Eur J Clin Pharmacol 2017;73:1615-21. [Ref.ID 102179]
8. Cita con resumen
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, for the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:28 de septiembre. [Ref.ID 102096]
9. Cita con resumen
Kuoppala J, Enlund H, Pulkkinen J, Kastarinen H, Jyrkkä J, Happonen P, Paajanen H. ACE inhibitors and the risk of acute pancreatitis — A population-based case–control study. Pharmacoepidemiol Drug Saf 2017;26:853-7. [Ref.ID 101965]
10. Cita con resumen
Anónimo. Gliptines: pancréatites. Prescrire 2017;37:262. [Ref.ID 101534]
11.Enlace a cita original Cita con resumen
Ariz MJ, Elizondo G. Nuevos antidiabéticos. ¿Qué lugar deben ocupar en terapéutica?. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-8. [Ref.ID 101436]
12. Cita con resumen
Butler PC. Glucagon-like peptide 1 drugs a second-line therapy for type 2 diabetes . JAMA Intern Med 2016;176:octubre. [Ref.ID 100561]
13.Tiene citas relacionadas Cita con resumen
Azoulay L, Filion KB, Platt RW, Dormuth CR, Clemens KK, Durand M, Hu N, Juurlink DN, Paterson JM, Targownik LE, Turin TC, Ernst P, and the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Association between incretin-based drugs and the risk of acute pancreatitis . JAMA Intern Med 2016:1 de octubre. [Ref.ID 100558]
14.Tiene citas relacionadas Cita con resumen
Luo H, Zhao L, Leung J, Zhang R, Liu Z, Wang X, Wang B, Nie Z, Lei T, Li X, Zhou W, Zhang L, Wang Q, Li M, Zhou Y, Liu Q, Sun H, Wang Z, Liang S, Guo X, Tao Q, Wu K, Pan Y, Fan D. Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography: a multicentre, singe-blinded, randomised controlled trial. Lancet 2016;387:2293-301. [Ref.ID 100389]
15.Tiene citas relacionadas
de Mestral C. Simple pharmacological prophylaxis for post-ERCP pancreatitis. Lancet 2016;387:2265-6. [Ref.ID 100359]
16.Tiene citas relacionadas Cita con resumen
Holman RR, Peterson ED. Sitagliptin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:2479. [Ref.ID 99762]
17.Tiene citas relacionadas Cita con resumen
Rutter MK, Wright AK, Ashcroft DM. Sitagliptin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:2478. [Ref.ID 99761]
18. Cita con resumen
Pi-Sunyer X, Astrup A, Fuijoka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Ortiz RV, Jensen CB, Wilding JPH, for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22. [Ref.ID 99228]
19. Cita con resumen
Anónimo. FDA approves two drugs for treatment of IBS with diarrhea. DIA Daily 2015:28 de mayo. [Ref.ID 99106]
20. Cita con resumen
Alonso A, MacLehose RF, Lutsey PL, Konety S, Chen LY. Association of amiodarone use with acute pancreatitis in patients with atrial fibrillation: a nested case-control study. JAMA Intern Med 2015;175:449-50. [Ref.ID 98967]
Seleccionar todas
 
 1 a 20 de 237 siguiente >>